

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**GRANT OF SHARE OPTIONS
AND
GRANT OF RESTRICTED SHARES**

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) announces that, on 29 April 2020, the Company has resolved to make grants of share options under the share option scheme adopted on 7 December 2015 (the “**Share Option Scheme**”) and restricted shares under the restricted share award scheme (the “**RSA Scheme**”) adopted on 22 March 2019.

THE GRANT OF SHARE OPTIONS

This section of the announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board is pleased to announce that on 29 April 2020 (the “**Date of Grant**”), 5,525,000 share options (the “**Option(s)**”) to subscribe for an aggregate of 5,525,000 ordinary shares of US\$0.001 each of the Company (the “**Share(s)**”) were granted to selected grantees (the “**Option Grantee(s)**”), subject to acceptance of the Option Grantees, under the Share Option Scheme. Details of the Options granted are set out as follows:

Date of Grant:	29 April 2020
Exercise price of Options granted:	HK\$13.840 per Share
Number of Options granted:	5,525,000 Options
Closing price of the Shares on the Date of Grant:	HK\$13.840 per Share
Average closing price per Share for the five business days immediately preceding the Date of Grant:	HK\$13.188 per Share
Validity period of the Options:	29 April 2020 to 28 April 2030, both date inclusive

None of the Option Grantees is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.

THE GRANT OF RESTRICTED SHARES

Reference is made to the announcement of the Company dated 22 March 2019 (the “**Announcement**”) in relation to the adoption of the RSA Scheme, a summary of the principal terms of which was set out in the Announcement. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Board is pleased to announce that on 29 April 2020, employees of the Company (the “**RSA Grantees**”) were granted 930,443 Restricted Shares (the “**RSA Shares**”), subject to acceptance of the RSA Grantees, pursuant to the RSA Scheme (the “**RSA Grant**”). Details of the RSA Grant are set out as follows:

Number of RSA Shares:	930,443 Restricted Shares, representing approximately 0.049% of the issued share capital of the Company as at the date of this announcement
RSA Grantees:	Employees of the Company and to the best knowledge of the Directors, none of the RSA Grantees is a director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company or associate (as defined in the Listing Rules) of any of them
Date of Grant:	29 April 2020
Market price of the Shares:	The closing price of the Shares on the Stock Exchange as at the date of grant of the Restricted Shares is HK\$13.840 per Share

The RSA Shares have been acquired by the Trustee through on-market transactions and are currently held by the Trustee in accordance with the Rules and the Trust Deed until the end of the relevant Vesting Date and be transferred to the RSA Grantees upon satisfaction of the relevant vesting conditions as may be specified by the Board at the time of making the RSA Grant. As no new Shares will be issued by the Company as a result of the RSA Grant, the RSA Grant will not result in any dilution effect on the shareholdings of existing shareholders of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 29 April 2020

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* For identification purposes only